Announcements
- Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
- New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
- Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
- Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
- Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024
- Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
- New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
- Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
- Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
- Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
More ▼
Key statistics
As of last trade Myriad Genetics Inc (MYD:STU) traded at 21.40, -8.55% below its 52-week high of 23.40, set on May 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 21.80 |
---|---|
High | 21.80 |
Low | 21.40 |
Bid | 21.40 |
Offer | 21.60 |
Previous close | 22.40 |
Average volume | 0.00 |
---|---|
Shares outstanding | 90.51m |
Free float | 88.62m |
P/E (TTM) | -- |
Market cap | 2.17bn USD |
EPS (TTM) | -2.82 USD |
Data delayed at least 15 minutes, as of May 23 2024.
More ▼